The elimination of 3,500 full-time employees at the FDA risks undermining the very innovation and domestic capacity the ...

China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Bi Jingquan, former head of the now-defunct China Food and Drug Administration (CFDA), is being investigated for suspected corruption, China's anti-graft watchdog said on Thursday.

U.S. Food and Drug Administration Commissioner Marty Makary described Chinese illicit vapes as a direct "attack" on the nation's youth.

Bi, 69, served as the chief of the China Food and Drug Administration from 2015 to 2018, when he introduced regulatory overhauls that spurred innovation in China’s pharmaceutical sector.

Historic changes are afoot for pharma as China gains ground on U.S. production. The pharma industry is projected to see ...

Review of foreign scientists from countries like China began even before three Chinese scientists in Michigan were caught ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

China's growing biotech prowess has become a real threat to the industry in the US in recent years. Moves by the Trump administration could weaken the US market further, according to several experts ...

Bi, 69, served as the chief of the China Food and Drug Administration from 2015 to 2018, when he introduced regulatory overhauls that spurred innovation in China’s pharmaceutical sector.